The European Commission has granted Protalix BioTherapeutics’ experimental treatment PRX-102 (pegunigalsidase alfa) Orphan Drug Designation for the treatment of Fabry disease, the company recently announced. The decision follows a European Medicines Agency (EMA) recommendation in November 2017, which stated the therapy may be of “significant benefit” to Fabry…
News
Amicus Therapeutics recently submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational oral medicine migalastat for treatment of patients 16 years and older with Fabry disease who have so-called “amenable” mutations. The NDA seeks migalastat’s approval in the U.S. as an alternative to intravenous enzyme…
Recent Posts
- FSIG marks 30 years of Fabry advocacy as new director takes the helm
- Patient-doctor perception gaps could affect Fabry disease management
- Gene therapy shows benefits in all participants in Fabry clinical trial
- Antibodies to Fabry treatment tied to infusion reaction risk
- I’m finally taking the increased risk of stroke in Fabry disease seriously